Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood. 2000;95(1):7–11.

Blood ◽  
2010 ◽  
Vol 116 (13) ◽  
pp. 2402-2402
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Population Based ◽  
High Dose ◽  
Newly Diagnosed ◽  
High Dose Therapy ◽  
Population Based Study ◽  
Stem Cell Support ◽  
Impact On Survival ◽  
Cell Support

Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004*

2010 ◽  
Vol 85 (3) ◽  
pp. 209-216 ◽  
Author(s):  
Annette J. Vangsted ◽  
Tobias W. Klausen ◽  
Niels F. Andersen ◽  
Niels Abildgaard ◽  
Anne O. Gang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Population Based ◽  
Late Relapse ◽  
High Dose ◽  
Population Based Study ◽  
Stem Cell Support ◽  
Dose Treatment ◽  
High Dose Treatment ◽  
Cell Support

Outcome for Patients with Leukemia, Multiple Myeloma and Lymphoma who Relapse After High Dose Therapy and Autologous Stem Cell Support

1996 ◽  
Vol 24 (1-2) ◽  
pp. 81-91 ◽  
Author(s):  
H. E. Johnsen ◽  
B. Björkstrand ◽  
K. Carlson ◽  
A. Gruber ◽  
A. Blystad ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
High Dose ◽  
High Dose Therapy ◽  
Stem Cell Support ◽  
Dose Therapy ◽  
Cell Support

scholarly journals Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database

2015 ◽  
Vol 90 (4) ◽  
pp. E73-E74 ◽  
Author(s):  
Morten O. Holmström ◽  
Peter Gimsing ◽  
Niels Abildgaard ◽  
Niels F. Andersen ◽  
Carsten Helleberg ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Early Death ◽  
High Dose ◽  
High Dose Therapy ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Dose Therapy ◽  
Cell Support

scholarly journals Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma

2012 ◽  
Vol 3 (2) ◽  
pp. 81-88
Author(s):  
Helge Menzel ◽  
Katarzyna Hinmüller ◽  
Hans-Jochem Kolb ◽  
Tibor Schuster ◽  
Alexander Hoellein ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Univariate Analysis ◽  
Progression Free Survival ◽  
High Dose ◽  
High Dose Therapy ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Dose Therapy ◽  
Cell Support

Objective: Induction high-dose chemotherapy followed by myeloablative melphalan (HD-Mel) treatment and autologous hematopoietic stem-cell support (autoSCT) is a standard treatment for multiple myeloma (MM) either upfront or in relapse after conventional treatment. We performed a retrospective analysis of consecutive patients undergoing a late repeat HD-Mel/autoSCT treatment for MM. Methods: Data from 24 consecutive patients with MM who underwent a myeloablative treatment with HD-Mel late after completion of upfront first high-dose therapy were assessed for toxicity, response, progression-free survival (PFS) and time to next treatment (TTNT). These data were correlated with the results obtained after the initial high dose therapy and autoSCT. Results: A total of 23 patients were treated with novel drugs (lenalidomide, thalidomide, bortezomib) after relapse to initial autoSCT. The median overall survival (OS) of all patients was 90 months. 19 patients (79%) achieved a very good partial remission (VGPR) or complete remission (CR) after initial autoSCT, compared with 42% after late autoSCT. PFS and TTNT were 19 and 24 months after initial compared with 13 and 21 months after late autoSCT. Univariate analysis identified initial response duration and the achievement of a CR/VGPR after the initial transplantation to be associated with prolonged response after repeat autoSCT. Conclusions: Our data indicate that late high-dose treatment followed by autoSCT is safe and effective after upfront intensive treatment, can bridge to allogeneic SCT, and encourage collection of an additional graft.

scholarly journals Aggressive neoplastic plasma cell growth with MLL gene rearrangement after high-dose therapy with autologous stem cell support for multiple myeloma

2001 ◽  
Vol 27 (5) ◽  
pp. 555-558 ◽  
Author(s):  
K Nishii ◽  
N Katayama ◽  
F Chen ◽  
E Usui ◽  
S Kadowaki ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Cell Growth ◽  
Plasma Cell ◽  
Gene Rearrangement ◽  
High Dose ◽  
High Dose Therapy ◽  
Stem Cell Support ◽  
Mll Gene Rearrangement ◽  
Cell Support

Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma

2001 ◽  
Vol 38 (3) ◽  
pp. 231-242 ◽  
Author(s):  
Athanasios Fassas ◽  
Guido Tricot
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
High Dose ◽  
Stem Cell Support ◽  
Dose Treatment ◽  
High Dose Treatment ◽  
Cell Support

Angiogenetic Factors and Biochemical Markers of Bone Metabolism in POEMS Syndrome Treated with High-Dose Therapy and Autologous Stem Cell Support

2006 ◽  
Vol 7 (1) ◽  
pp. 73-76 ◽  
Author(s):  
Efstathios Kastritis ◽  
Evangelos Terpos ◽  
Athanasios Anagnostopoulos ◽  
Irini Xilouri ◽  
Meletios Athanasios Dimopoulos
Keyword(s):  
Stem Cell ◽  
Bone Metabolism ◽  
Biochemical Markers ◽  
Poems Syndrome ◽  
High Dose ◽  
High Dose Therapy ◽  
Stem Cell Support ◽  
Dose Therapy ◽  
Cell Support
Sign in / Sign up

Export Citation Format

Share Document